Copyright
©The Author(s) 2021.
World J Gastroenterol. Aug 21, 2021; 27(31): 5181-5188
Published online Aug 21, 2021. doi: 10.3748/wjg.v27.i31.5181
Published online Aug 21, 2021. doi: 10.3748/wjg.v27.i31.5181
Ref. | Study type | Cancer type | Results |
Torres et al[18] | Prospective observation study | Hematological tumor (n = 50) | A hepatitis flare occurred in 10% of HCV-infected cancer patients receiving chemotherapy |
Non-HCC solid tumor (n = 50) | Definition of HCV-related hepatitis flare: unexplained increase in ALT to 3 times the upper limit of normal and increase in HCV-RNA level of ≥ 1 log10 IU/mL over baseline | ||
Li et al[4] | Retrospective observation study | Hematological tumor (n = 569); HCC (n = 256); Non-HCC solid tumor (n = 3900) | The incidence of severe acute liver injury in HCV-infected hematological cancer patients was higher than that in those with HCC patients and non-HCC solid tumor patients (9.4% vs 1.9 % and 1.1%, respectively). Definition of severe acute liver injury: ALT increased beyond 10 times the upper limit of normal during chemotherapy or 6 months following chemotherapy |
Tomizawa et al[28] | Retrospective observation study | Colorectal cancer (n = 24) | The incidence of severe acute exacerbation rate in HCV-infected patients was 8%. Definition of severe acute exacerbation: ALT increased beyond 5 times the upper limit of normal |
Hsu et al[22] | Retrospective observation study | Hematological tumor (n = 104); Solid tumor (n = 204) | The incidence of HCV acute exacerbation was 11% (hematological tumor: 23%; solid tumor: 4.4%). Definition of HCV acute exacerbation: 3-fold or greater increase in serum ALT level |
- Citation: Li YR, Hu TH, Chen WC, Hsu PI, Chen HC. Screening and prevention of hepatitis C virus reactivation during chemotherapy. World J Gastroenterol 2021; 27(31): 5181-5188
- URL: https://www.wjgnet.com/1007-9327/full/v27/i31/5181.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i31.5181